Faron reports 85% response rate in frontline higher-risk MDS trial of bexmarilimab combination

Bitget2026/11/04 14:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Faron Pharmaceuticals will present five abstracts on bexmarilimab, Clever-1 biology and higher-risk MDS at ASH in New Orleans, December 12-15, 2026.
BEXMAB survival outcomes varied by TP53 mutation status, with the longest survival observed in previously treated patients without TP53 mutations.
Previously reported frontline results showed remissions with bexmarilimab combined with azacitidine; its safety profile appeared comparable to azacitidine alone.
The randomized Phase 2b BEXERA trial targets approximately 90 previously untreated patients to select a bexmarilimab dose for Phase 3 development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Faron reports 85% response rate in frontline higher-risk MDS trial of bexmarilimab combination

You may also like

Crypto prices